We would love to hear your thoughts about our site and services, please take our survey here.
Tony joined Avacta from AHR, an international architecture and building consultancy practice, where he has held the role of Finance Director since 2011.
Not the experience you want doing billion pound deals…..
Winging it ….
Resign Gardiner you out of your depth and have cost thousands of LTH’s a massive drop in their net worth.
Everyone needs to hold to get back in the black, but we can’t let this man run the finance’s any longer with multi billion pound deals coming soon, use your votes at AGM to get rid.
Smith departed to the mountain bunker and stayed there for 40 days and nights in order to receive the 50p placing.
He was kept silent while the company has lost over half its value in that time because of the rules of his placement.
Pitch forks are out now and X (twitter) SH’s want him out.
I prefer Gardiner to go first with Smith moved sideways.
Yanks know about us….
Paula Takacs Foundation.
Since our inception in 2010, we have emerged one of the most active grassroots sarcoma foundations in the U.S.
https://paulatakacsfoundation.org/about-us/
https://paulatakacsfoundation.org/soft-tissue-sarcoma-pipeline-insight/
Little Avacta gets a mention.
* In September 2022, Avacta Group plc announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using the pre|CISION technology so that it is activated predominantly in the tumor with the aim of sparing healthy tissue from exposure and improving the safety, tolerability, and efficacy of the drug.
WET Cancer on here
jonathan his**** (born april 1974)[1] is a british hedge fund manager and founder of gsa capital, a london-based hedge fund.
shame on him shorting a company trying to save lives.
i wonder if the big c comes a knocking at his door or family members
Smith can’t be defended and needs to pull a bloody big rabbit out the bag to save his bacon.
Won’t do a deal with smaller companies so he gets a bigger deal later on.???
Just do a deal secure the cash and let BP decide what they are going to do about the smaller deals already done,If it’s the Holy Grail they will buy them out as well.
Just get LTH’s back in the black from the bloody car crash of a placing.
3 years of empty promises and kicking the can down the road.
LTH’ s need to see some action and answers from this board.
Ten Bob Tony won 7/1 at Newmarket today
Bloody hell 50p Tony Gardiner 😂😂
Pre|CISION+
Just came out the blue or have they working on this for a while, is this the reason Smith said “ funding don’t worry about that”
As soon as this patent is approved we could see some action in SP.
That haven’t commercialised Pre/Cision
But have now moved onto Pre/Cision +
I have a feeling there is a Major announcement coming very soon…
The Avacta pre|CISION+ platform is based on the peptide drug conjugate delivery model which is then conjugated to a biologic protein moiety such as the Fc region of an antibody or AffimerXT® to significantly extend the half-life and optimise the pharmacokinetics of the peptide drug conjugate.
Significant extension of the half-life of the pre|CISIONTM warhead will benefit certain warheads that target tumours differently from traditional cytotoxics. Examples of such pre|CISION+ warheads include cancer pathway targeted therapies or immune modulators where more consistent and concentrated delivery to the TME is optimal.
WET Cancer go away
Has any company ever presented chemo results to the FDA with so little side effects.
Would it not be ethical that the FDA approve as quick as possible.
These results must set a precedent on the grounds of safety even if showing just the efficacy shown so far.
Why would LG Chem,Daewoong and Eli Lilly
All pay $180m LG Chem,
Daewoong give 25% of Affxell,
Eli Lilly pay licence fee on Point Bio deal.
When any of them only has to offer a cheeky T/O price now to test PI’s patience.
II’s still the minority in this company.
At £180m MCap, Smith & Gardiner and the board have put Avacta on a very dangerous position.
LG Chem
This multi-target therapeutics development agreement provides for upfront and near-term milestone payments, plus longer-term clinical development milestones totalling $180million.
Daewoong
The second milestone will result in an increase in Avacta's shareholding in AffyXell, which currently stands at 19%. The exact shareholding will be determined, as with the first milestone payment which was achieved in April 2022, following a formal valuation of AffyXell.
Our presentation at #AACR24 today - well received with many intriguing conversations.
Grateful and humbled by our lead author Prof @udai_banerji who did not stop speaking for 3.5 hours. Udai - much appreciated
#PeptidesCreateHope
#LetsDoThis
Cancer medications granted accelerated approval are often confirmed despite not demonstrating a benefit in overall survival or quality of life.
In a separate analysis, researchers looked at the reasons why drugs granted accelerated approval between 2013 and 2023 were converted to regular approval. They found that 40% were based on how long people survived, the gold standard for cancer medicines. Another 44% were based on how long people went without their cancer growing; 10% were based on finding that tumors shrank, called response rate, and the duration of that response; and 4% were based on response rate alone. One drug received regular approval despite a confirmatory trial that found no difference in overall survival or time to cancer recurrence between patients receiving the new treatment and those getting the existing standard of care.
Reading this with data Avacta has stated it’s hard not to see AVA6000 approved…..
https://www.cancertodaymag.org/cancer-talk/results-that-matter/?utm_medium=twitter&utm_source=social&sf187596192=1
Gardener working on his abacus now with his Dick Turpin mask on working out how many more free shares he should award to himself and Smith.
Avacta present their poster on day 5 of the AACR Conference.
Simon Bennett Chief Business Officer will have had 4 full days of meetings with BP before the poster,could we get a LD announced next week…
Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
RNS. 5 April 2023
Avacta Group plc
("Avacta" and, together with its subsidiary undertakings, the "Group")
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
All patients still on drug
RAH twitter
That’s 12 months on drug….WOW
Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
How many meetings has Simon scheduled
Sadly just a rehash of December data as I expected but not what I hoped for. Oh well roll on the webinar.
Touk you are a P. Rick